Intelligo

Private limited company · Oslo

DNE PHARMA AS

ActiveWholesale of pharmaceutical and medical goods (46.460)

Founded
13 Sep 2007
Employees
5
Chief executive
Geir Ove Engeset
Business address
Karihaugveien 22, 1086 Oslo

The life line 2007–2026

Operating revenue per year, with recorded events above. As a table

Operating revenue 2025: NOK 217.8m.

  1. Chair took office§ 07
  2. Managing director took office§ 07
  3. Founded§ 16

Sources: the Register of Company Accounts (company accounts), fetched 15 Nov 2026; the Brønnøysund Register Centre. Each event has the colour of the section it is in.

In brief

DNE PHARMA AS is a private limited company in Oslo, founded in 2007, in the industry wholesale of pharmaceutical and medical goods. The chief executive is Geir Ove Engeset, and the chair of the board is Esther Elisabeth Paust. In 2025 the company had NOK 217.8m in operating revenue and a net profit of NOK 136.2m. The largest owner is FARMA INVESTMENT AS with 100.0%.

Put together by Intelligo from the sections below; each figure stands with its source where it belongs.

Overview

§ 01 Latest changes

4 changes, latest 30 Aug 2026

  • Annual accounts filed 2024 → 2025
  • Godkjent årsregnskap
  • Won a tender from Amgros I/S
  • Lost a tender: Läkemedel på rekvisition 2025 SLL450

Source: the Brønnøysund Register Centre and Intelligo's own observations, fetched 15 Nov 2026 · All events →

Overview

§ 02 Worth knowing

None registered

None of the rules apply.The rules are fixed: bankruptcy, missing annual accounts, three years of losses, negative equity and the like. Checked 15 Nov 2026.

Overview

§ 03 Key figures

Revenue NOK 217.8m in 2025

Revenue

NOK 217.8m

+249.4% from 2024

20232025

Operating profit

NOK 169.8m

+1,401.6% from 2024

20232025

Net profit

NOK 136.2m

+1,431.1% from 2024

20232025

Equity

NOK 73.6m

+37.9% from 2024

20232025

Source: the Register of Company Accounts, read 15 Nov 2026 · The full accounts →

Finances

§ 04 Where the money comes from and goes

Financial year 2024

Of every krone of operating revenue in 2024:

  • Wages and social costs 14%
  • Depreciation 5%
  • Other operating costs 29%
  • Not specified in the source 35%
  • Left as operating result 18%

Of the net profit for 2024, NOK −6.1m stayed in the company. The rest, NOK 15.0m, is an assumed dividend.

The assumed dividend is derived by Intelligo from the change in equity, not stated by the source. Source: the Register of Company Accounts via areg.no, read 15 Nov 2026

Finances

§ 05 Financial health

Equity ratio 29.1%

RevenueNOK 217.8m Operating margin78.0% Equity ratio29.1% Revenue growth+249.4%
  • DNE PHARMA AS, 2025
  • Industry median, assumed: NOK 8.5m · 4.3% · 41.6% · +7.3%

Equity NOK 73.6m29% of the assets (NOK 252.5m)

Source: the Register of Company Accounts, read 15 Nov 2026. The median is derived by Intelligo from 538 companies in 46.460 Wholesale of pharmaceutical and medical goods, not stated by the source.

Finances

§ 06 Accounts

19 years, latest 2025

NOK 1,0002023–25202520242023
Operating revenue217,78062,32854,192
Operating profit169,78311,3079,159
Profit before tax174,66011,4098,410
Net profit136,2348,8986,607
Total assets252,50596,52983,399
Equity73,58653,36859,470
Liabilities178,91943,16123,929

Source: the Register of Company Accounts, read 15 Nov 2026 · All 19 years →

Management and ownership

§ 07 Officers

4 officers now

The board: 2 members

Source: the Brønnøysund Register Centre, read 23 Oct 2026 · All 4 roles, former ones too →

Management and ownership

§ 08 Signature, procuration and authorisations

May sign for the company:

To styremedlemmer i fellesskap eller daglig leder og styrets leder i fellesskap.

Procuration: none registered.

The signature is word for word from the register. Source: the Register of Business Enterprises, read 24 Aug 2026

Management and ownership

§ 09 Owners

1 shareholder · largest 100.0%

OwnerShare
FARMA INVESTMENT AS
100.0%

Source: the Tax Administration's Register of Shareholders as of 31 December 2025, read 31 Jul 2026 · All 1 owners →

Management and ownership

§ 10 Group

1 subsidiary

DNE PHARMA AS parent company

Share held. Source: the Tax Administration's shareholder register, fetched 31 Jul 2026 · The whole group →

Management and ownership

§ 11 Portfolio

None registered

No holdings registered.The shareholder register has no shares held by the company. Checked 15 Nov 2026.

Management and ownership

§ 12 Network

9 connections

  • Person
  • Company

2 people link DNE PHARMA AS to 5 other companies: Geir Ove Engeset 3 and Esther Elisabeth Paust 3.

Source: the Brønnøysund Register Centre, read 23 Oct 2026 · Explore the network →

Events and registers

§ 13 Events

43 since 2015

Events per year

20152026

  • Notices70
  • Register changes1
  • Tenders won1

Since 2015: 70 announcements, 1 register change and 1 tender won. Most happened in 2015 and 2016.

Source: the announcements of the Brønnøysund Register Centre, the Tax Administration's Register of Shareholders, Doffin, TED and NAV, read 1 Nov 2026. Register changes are Intelligo's own observations. · All 43 events →

Events and registers

§ 14 Notices

70, latest 22 Aug 2026

  • Godkjente årsregnskap
  • Godkjente årsregnskap
  • Godkjente årsregnskap

Source: The Brønnøysund Register Centre's announcements ↗, read 1 Nov 2026 · All 70 →

Events and registers

§ 15 Charges

Not fetched yet

Events and registers

§ 16 Other registers

Found in 3 of 7

  • The Central Coordinating RegisterRegistered 17 Oct 2007
  • VATRegistered
  • The Register of Business EnterprisesRegistered 17 Oct 2007
  • The Cleaning RegisterNot registered
  • The Register of Staffing AgenciesNot registered
  • Smiley scheme, the Norwegian Food Safety AuthorityNot registered
  • The Financial Supervisory Authority's licence registerNot registered

Purpose: Selv, gjennom hel eller deleide selskaper eller ved samarbeide med andre virksomheter, å drive handel og utvikling med og av farmasøytiske produkter, herunder legemidler, samt annen forretningsmessig virksomhet forbundet hermed.

Source: the Brønnøysund Register Centre, the Labour Inspection Authority, the Food Safety Authority and the Financial Supervisory Authority, each on its own, fetched 15 Nov 2026

Market

§ 17 Tenders

3 tenders

  • 2025
  • 2025
  • 2025
  • Won
  • Lost
AwardedContractBuyerOutcome
Oct 2025Amgros 2026 1.1210.aAmgros I/SWon
—Läkemedel på rekvisition 2025 SLL450Region Stockholm - ServiceförvaltningenLost
—Läkemedel 2025 del 1Region Skåne, Koncernstab inköp och ekonomistyrningLost

Source: Doffin and TED, read 25 Jul 2026. · All 3 tenders →

Market

§ 18 Vacancies

None registered

No vacancies.No open ads at NAV. Checked 15 Nov 2026.

Market

§ 19 Competitors

Industry code 46.460

The companies most like it:

Compare them

The selection is Intelligo's, not stated by the source: companies met in tenders and winners of tenders of the same kind, otherwise the same industry code, nearest in place and size. Source: the Brønnøysund Register Centre, Doffin and TED, fetched 15 Nov 2026 · All competitors → · Largest in the industry →

Last

§ 20 Questions and answers

7 questions

  • Who is the chief executive of DNE PHARMA AS?
    Geir Ove Engeset, since 2023. § 07
  • Who owns DNE PHARMA AS?
    1 shareholder. It is FARMA INVESTMENT AS with 100.0%. § 09
  • What was the revenue in 2025?
    NOK 217.8m in the company. § 06
  • Who can sign for DNE PHARMA AS?
    To styremedlemmer i fellesskap eller daglig leder og styrets leder i fellesskap. § 08
  • Who is the auditor?
    HØILUND REVISJON AS, from 25 Jan 2022. § 07
  • Where is DNE PHARMA AS based?
    Karihaugveien 22, 1086 Oslo.
  • When was DNE PHARMA AS founded?
    13 Sep 2007, registered in the Register of Business Enterprises 17 Oct 2007. § 16

The answers come from the sections linked to, with their sources.

01Latest changesOverviewContentsClose